RxDoctor Payments Data

Abubakir Baban, NP

Nurse Practitioner · Dearborn, MINPI 1740964527

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $111,763 of the $142,905 with a category attached, or 78.2%. Every reported general payment came from a single manufacturer, Neurocrine Biosciences, Inc.. Among nurse practitioner clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$142,905in general payments, 2019–2025

Across 227 payments — averaging $629.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$143K

What the payments were for

  • Consulting fees$6,7505%
  • Speaking & faculty fees$111,76378%
  • Travel & lodging$19,45414%
  • Food & beverage$4,9393%

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Neurocrine Biosciences, Inc.227$142,905

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$142,905 in reported general payments places this provider in the 95th percentile of 3,351 nurse practitioner providers in Michigan.

See all nurse practitioner providers in Michigan

Medicare billing

Part B allowed, 2024
$31,154
Medicare patients
104
Services billed
331

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate44$360,927
EliquisApixaban29$8,498
Lantus SolostarInsulin Glargine,hum.Rec.Anlog30$3,388
Breo ElliptaFluticasone/Vilanterol12$3,088
Fluticasone-SalmeterolFluticasone Propion/Salmeterol11$2,670
Atorvastatin Calcium78$1,810
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen56$1,203
Tramadol Hcl26$978
Potassium Chloride13$855
Losartan Potassium41$649
Gabapentin48$622
Albuterol Sulfate HfaAlbuterol Sulfate18$617
Acetaminophen-CodeineAcetaminophen With Codeine18$549
Hydralazine Hcl25$495
Divalproex Sodium16$442

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$142,905$360,92744 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,351 nurse practitioner providers in Michigan.

Other nurse practitioner in Dearborn

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →